Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation

M. Lopez-Meseguer, C. Berastegui, V. Monforte, C. Bravo, E. Domingo, A. Roman

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Background Accepted treatment for severe pulmonary arterial hypertension (PAH) includes intravenous epoprostenol and lung transplantation (LT). Inhaled iloprost plus oral sildenafil (Ilo-Sil) is an alternative strategy that may also delay the need for LT. Patients and Methods This was a long-term descriptive study in eight patients with PAH functional class (FC) IV with right heart failure, four of them potential candidates for LT, who were treated with Ilo-Sil as an alternative to epoprostenol. Results At the start of the study, patients (seven women; mean age, 43.8 [range, 34-66] years) were in FC IV and unable to perform the 6-minute walk test. Mean cardiac index was 1.9 (range, 1.4-2.1) L/min/m2. Treatment with Ilo-Sil provoked a rapid and sustained improvement; mean walking distance at 3 months was 322 ± 90 m and no patient remained in FC IV. Survival at 1 and 5 years was 100% and 75%, respectively. Of the four potential LT candidates, one underwent transplantation after 6.8 years and one died after 1.2 years. Conclusions These results suggest that therapy with Ilo-Sil represents an acceptable alternative in patients with severe and unstable PAH. © 2013 Elsevier Inc.
Original languageEnglish
Pages (from-to)2347-2350
JournalTransplantation Proceedings
Volume45
Issue number6
DOIs
Publication statusPublished - 1 Jul 2013

Fingerprint Dive into the research topics of 'Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation'. Together they form a unique fingerprint.

Cite this